Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arfolitixorin with 5-fluorouracil-based first-line treatment regimens for metastatic colorectal cancer
2024-516802-43-00Phase 2Authorised
- Sponsor
- Isofol Medical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of arfolitixorin in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Isofol Medical. Primary endpoints: Number and severity of adverse events, Objective response rate and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
arfolitixorin
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-516802-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516802-43-00.